VANCOUVER, BC, Oct. 26, 2020 /CNW/ - Sirona Biochem Corp.
(TSXV: SBM) (FSE: ZSB) (USOTC:
SRBCF) ("Sirona") is pleased to announce that the
clinical study using .2% TFC-1067 and conducted by Dr. Zoe Draelos of Dermatology Consulting Services,
North Carolina, has been peer
reviewed and accepted for publication in the Journal of Cosmetic
Dermatology.
The study abstract can be found at the following link:
https://doi.org/10.1111/jocd.13771
"The acceptance of a peer-reviewed study in a prestigious
dermatology journal shows the dedication and credibility of our
team and unwavering support of our innovative compound TFC-1067,"
said Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer
of Sirona Biochem. "While we continue to foster our global
partnerships, this publication will provide tremendous of
commercial value as consumers increasingly demand clinical
validation of products. With the unique benefits of TFC-1067
demonstrated in this trial, we are very excited about the next
clinical trial currently underway using a higher concentration and
improved formulation" she added.
The 12-week double blinded study involving 48 participants,
completed in 2019, showed that TFC-1067 successfully achieved the
endpoint of lightening dyschromic areas (dark spots) on the skin.
With the application of TFC-1067, areas of hyperpigmentation were
significantly lightened while preserving overall skin tone.
TFC-1067 demonstrated the ability to lighten dark spots to blend
into surrounding skin while preserving overall complexion. In this
study, TFC-1067 achieved this goal while Hydroquinone did not,
which is a tremendous consumer benefit and commercial
advantage.
Further studies are planned, with one currently underway.
Exploring the potential of TFC-1067 on different skin types,
formulations and concentrations will further unlock the consumer
and commercial unique benefits.
Hydroquinone has remained the gold standard for skin lightening
despite known toxicity which is an ongoing concern for the FDA and
the dermatology community. Hydroquinone is banned or has restricted
dosing in an increasing number of countries. Despite the fact that
many non-hydroquinone alternative lightening compounds are either
toxic or ineffective, unfortunately millions of people still resort
to toxic treatments for hyperpigmentation despite poor aesthetic
results. There is a clear unmet need for a safe and effective
treatment in this 20-Billion-USD skin
lightening market.1
About the Journal of Cosmetic Dermatology
The Journal of Cosmetic Dermatology is the
official journal of the International Academy of Cosmetic
Dermatology (IACD) and the Canadian Association of Aesthetic
Medicine (CAAM). The Journal publishes high quality, peer-reviewed
articles on all aspects of cosmetic dermatology with the aim to
foster the highest standards of patient care in cosmetic
dermatology. Published quarterly, the Journal of Cosmetic
Dermatology facilitates continuing professional
development and provides a forum for the exchange of scientific
research and innovative techniques.
For more information about the Journal of Cosmetic Dermatology,
please
visit: https://onlinelibrary.wiley.com/page/journal/14732165/homepage/productinformation.html
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
_____________________________________
1Fact.MR
(July 2018) Retrieved from:
https://globenewswire.com/news-release/2018/07/10/1535161/0/en/Key-Insights-on-Skin-Lightening-Products-Market-through-2022-by-Fact-MR.html
SOURCE Sirona Biochem Corp.